What makes a good drug target?

被引：123

作者：

Gashaw, Isabella ^{[1
]}

Ellinghaus, Peter ^{[2
]}

Sommer, Anette ^{[1
]}

Asadullah, Khusru ^{[1
]}

机构：

[1] Bayer HealthCare, Global Drug Discovery Target Discovery, D-13342 Berlin, Germany

[2] Bayer HealthCare, Global Drug Discovery Target Discovery, D-42096 Wuppertal, Germany

来源：

DRUG DISCOVERY TODAY | 2011年 / 16卷 / 23-24期

关键词：

INHIBITION; SORAFENIB; DISCOVERY; OPINION;

D O I：

10.1016/j.drudis.2011.09.007

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Novel therapeutics in areas with a high unmet medical need are based on innovative drug targets. Although 'biologicals' have enlarged the space of druggable molecules, the number of appropriate drug targets is still limited. Discovering and assessing the potential therapeutic benefit of a drug target is based not only on experimental, mechanistic and pharmacological studies but also on a theoretical molecular druggability assessment, an early evaluation of potential side effects and considerations regarding opportunities for commercialization. This article defines key properties of a good drug target from the perspective of a pharmaceutical company.

引用

页码：1037 / 1043

页数：7

共 50 条

[1] Phase II failures: 2008-2010 [J].

Arrowsmith, John .

NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (05) :1-1

[2] TRIAL WATCH Phase III and submission failures: 2007-2010 [J].

Arrowsmith, John .

NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (02) :1-1

[3]

Asadullah K., 2011, BIOMARKERS S1, V16, P1

[4] Properties and identification of human protein drug targets [J].

Bakheet, Tala M. ;

Doig, Andrew J. .

BIOINFORMATICS, 2009, 25 (04) :451-457

[5] Current prospects for RNA interference-based therapies [J].

Davidson, Beverly L. ;

McCray, Paul B., Jr. .

NATURE REVIEWS GENETICS, 2011, 12 (05) :329-340

[6] Animalgesic effects [J].

Dolgin, Elie .

NATURE MEDICINE, 2010, 16 (11) :1237-1240

[7] The target discovery process [J].

Egner, U ;

Krätzschmar, J ;

Kreft, B ;

Pohlenz, HD ;

Schneider, M .

CHEMBIOCHEM, 2005, 6 (03) :468-479

[8] A structural biology view of target drugability [J].

Egner, Ursula ;

Hillig, Roman C. .

EXPERT OPINION ON DRUG DISCOVERY, 2008, 3 (04) :391-401

[9]

Ekins S, 2007, METH MOL B, V356, P319

[10] Selective inhibition of BET bromodomains [J].

Filippakopoulos, Panagis ;

Qi, Jun ;

Picaud, Sarah ;

Shen, Yao ;

Smith, William B. ;

Fedorov, Oleg ;

Morse, Elizabeth M. ;

Keates, Tracey ;

Hickman, Tyler T. ;

Felletar, Ildiko ;

Philpott, Martin ;

Munro, Shonagh ;

McKeown, Michael R. ;

Wang, Yuchuan ;

Christie, Amanda L. ;

West, Nathan ;

Cameron, Michael J. ;

Schwartz, Brian ;

Heightman, Tom D. ;

La Thangue, Nicholas ;

French, Christopher A. ;

Wiest, Olaf ;

Kung, Andrew L. ;

Knapp, Stefan ;

Bradner, James E. .

NATURE, 2010, 468 (7327) :1067-1073

← 1 2 3 4 5 →